Assessment of Pertussis Underreporting in Italy
- PMID: 36902519
- PMCID: PMC10003430
- DOI: 10.3390/jcm12051732
Assessment of Pertussis Underreporting in Italy
Abstract
A study was conducted to assess the degree of pertussis underreporting in Italy. An analysis was performed to compare the frequency of pertussis infections estimated using seroprevalence data with the pertussis incidence based on reported cases among the Italian population. For this purpose, the proportion of subjects who had an anti-PT ≥ 100 IU/mL (indicative of B. pertussis infection within the last 12 months) was compared with the reported incidence rate among the Italian population ≥5 years old, divided into two age groups (6-14 and ≥15 years old), obtained from the European Centre for Disease Prevention and Control (ECDC) database. The pertussis incidence rate in the Italian population ≥5 years old reported by the ECDC in 2018 was 6.75/100,000 in the 5-14 age group and 0.28/100,000 in the ≥15 age group. The proportion of subjects recruited in the present study with an anti-PT ≥ 100 IU/mL was 0.95% in the 6-14 age group and 0.97% in the ≥15 age group. The estimated rate of pertussis infections based on seroprevalence was approximately 141-fold and 3452-fold higher than the reported incidence in the 6-14 age group and in the ≥15 age group, respectively. Quantification of underreporting can allow for the burden of pertussis, as well as the impact of ongoing vaccination, to be better evaluated.
Keywords: pertussis; seroprevalence; underreporting.
Conflict of interest statement
G.G. reports having received personal fees for advisory board membership and consultancy from Emergent BioSolutions, the GSK group of companies, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur Italy, Moderna, and Seqirus, as well as personal fees for lectures from Merck Sharp & Dohme, Pfizer, and Seqirus, outside the submitted work. F.B., T.G., M.S., M.C.R., T.B., C.V., F.N., and C.M.T. declare no conflicts of interest.
Figures
Similar articles
-
Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013).J Med Microbiol. 2016 Jul;65(7):649-657. doi: 10.1099/jmm.0.000264. Epub 2016 Apr 13. J Med Microbiol. 2016. PMID: 27075481
-
Seroprevalence of diphtheria and pertussis immunoglobulin G among children with pneumonia in Ji'nan, China.BMC Pediatr. 2018 Dec 5;18(1):383. doi: 10.1186/s12887-018-1337-y. BMC Pediatr. 2018. PMID: 30518371 Free PMC article.
-
[Seroprevalence of pertussis toxin antibody in Manisa province of Turkey, after six years implementation of acellular pertussis vaccine].Mikrobiyol Bul. 2018 Apr;52(2):180-189. doi: 10.5578/mb.57534. Mikrobiyol Bul. 2018. PMID: 29933735 Turkish.
-
Seroprevalence studies of pertussis: what have we learned from different immunized populations.Pathog Dis. 2015 Oct;73(7):ftv050. doi: 10.1093/femspd/ftv050. Epub 2015 Jul 24. Pathog Dis. 2015. PMID: 26208655 Review.
-
Epidemiology of pertussis.Pediatr Infect Dis J. 2005 May;24(5 Suppl):S10-8. doi: 10.1097/01.inf.0000160708.43944.99. Pediatr Infect Dis J. 2005. PMID: 15876918 Review.
Cited by
-
Public health management of pertussis in adults: Practical challenges and future strategies.Hum Vaccin Immunother. 2024 Dec 31;20(1):2377904. doi: 10.1080/21645515.2024.2377904. Epub 2024 Jul 17. Hum Vaccin Immunother. 2024. PMID: 39016172 Free PMC article. Review.
-
Knowledge and attitude factors associated with the prevalence of Tdap (tetanus, diphtheria, and acellular pertussis) booster vaccination in healthcare workers in a large academic hospital in Southern Italy in 2022: a cross-sectional study.Front Public Health. 2023 Jul 13;11:1173482. doi: 10.3389/fpubh.2023.1173482. eCollection 2023. Front Public Health. 2023. PMID: 37522000 Free PMC article.
-
Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care.Infect Dis Rep. 2024 Sep 2;16(5):870-879. doi: 10.3390/idr16050068. Infect Dis Rep. 2024. PMID: 39311209 Free PMC article.
-
Pertussis Epidemiology in the Autonomous Province of Vojvodina, Serbia, 1948-2023.Vaccines (Basel). 2024 May 10;12(5):525. doi: 10.3390/vaccines12050525. Vaccines (Basel). 2024. PMID: 38793776 Free PMC article.
-
Assessing the Underestimation of Adult Pertussis Disease in Five Latin American Countries.Infect Dis Ther. 2023 Dec;12(12):2791-2806. doi: 10.1007/s40121-023-00895-x. Epub 2023 Dec 14. Infect Dis Ther. 2023. PMID: 38095808 Free PMC article.
References
-
- WHO Pertussis vaccines: WHO position paper—August 2015. Wkly. Epidemiol. Rec. 2015;35:433–460. - PubMed